Merck KGaA (OTCMKTS:MKKGY) Given Average Rating of “Hold” by Brokerages

Shares of Merck KGaA (OTCMKTS:MKKGY) have been assigned an average rating of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation.

A number of brokerages have weighed in on MKKGY. HSBC raised Merck KGaA to a “hold” rating in a research report on Monday, July 6th. Jefferies Financial Group began coverage on Merck KGaA in a research note on Tuesday, May 26th. They set a “hold” rating for the company. UBS Group lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. Finally, Zacks Research cut Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th.

Merck KGaA Stock Up 0.8%

Shares of MKKGY stock opened at $32.73 on Friday. Merck KGaA has a 52-week low of $23.73 and a 52-week high of $34.19. The stock has a market cap of $21.15 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 2.66 and a beta of 0.98. The firm’s 50-day moving average is $32.37 and its 200-day moving average is $29.46. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.00 and a current ratio of 1.51.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.